Treatment of psoriasis with fumaric acid esters: Results of a prospective multicentre study

British Journal of Dermatology

Volumn 138, Issue 3, 1998, Pages 456-460

  Mrowietz, U ^a   Christophers, E ^a   Altmeyer, P ^b  

^a UNIVERSITY OF KIEL   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FUMADERM; FUMARIC ACID DIMETHYL ESTER; FUMARIC ACID ETHYL ESTER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CITRIC ACID CYCLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; EOSINOPHILIA; FEMALE; GASTROINTESTINAL SYMPTOM; HOT FLUSH; HUMAN; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PRURITUS; PSORIASIS VULGARIS; TABLET;

ADULT; AGED; DERMATOLOGIC AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FUMARATES; GASTROINTESTINAL DISEASES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSORIASIS; TREATMENT OUTCOME;

EID: 0031896129     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.1998.02124.x     Document Type: Article

References (14)

1. Schweekendiek W. Heilung von Psoriasis. Med Monatscher 1959; 13: 103-4.
2. Nieboer C, de Hoop D, Langendijk PNJ et al. Fumaric acid therapy in psoriasis: a double-blind comparison between fumaric acid compound therapy and monotherapy with dimethylfumaric acid ester. Dermatologica 1990; 181: 33-7.
3. Kolbach DN, Nieboer C. Fumaric acid therapy in psoriasis: results and side-effects of 2 years of treatment. J Am Acad Dermatol 1992; 27: 769-71.
4. Altmeyer P, Matthes U, Pawlak F et al. Antipsoriatic effect of fumaric acid derivatives. Results of a multicentre double-blind study in 100 patients. J Am Acad Dermatol 1994; 30: 977-81.
5. Thio HB, van der Sehroeff JG, Nugteren-Huying WM, Vermeer BJ. Long-term systemic therapy with dimethylfumarate and monoethylfumarate (Fumaderm) in psoriasis. J Eur Acad Dermatol Venereol 1995; 4: 35-40.
6. Nugteren-Huying WM, van der Schroeff JG, Hermans J, Suurmond D. Fumaric acid therapy for psoriasis: a randomized. double-blind. placebo-controlled study. J Am Acad Dermatol 1990; 22: 311-12.
7. Altmeyer P, Höxtermann S, Auer T. Verlaufsbeobachtungen der Lymphozytensubpopulationen bei Psoriasis-Patienten unter oraler Therapie mit Fumaraten. Akt Dermatol 1996; 22: 272-7.
8. Sebök B, Bonnekoh B, Geisel J, Mahrle G. Antiproliferative and cytotoxic profiles of antipsoriatic fumaric acid derivatives in keratinocyte cultures. Eur J Pharmacol 1994; 270: 79-87.
9. Sebök B, Bonnekoh B, Mahrle G. IL-1 alpha-induced expression of ICAM-1 on cultured hyperproliferative keratinocytes: suppression by antipsoriatic dimethyl-fumarate. Int J Dermatol 1994; 33: 367-70.
10. Petres J, Kalkhoff KW, Baron D et al. Der Eintluss von Fumarsäur-emonoethylester auf die Nukleinsäure-und Proteinsynthese PHA-stimulierter menschlicher Lymphozyten. Arch Dermatol Res 1975; 251: 295-300.
11. De Jong P, Bezemer AC, Van Zomerdijk TPL et al. Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate. Eur J Immunol 1996; 26: 2067-74.
12. Christophers E. The immunopathology of psoriasis, Int Arch Allergy Immunol 1996; 110: 199-206.
13. Bartels J, Moshisuki M, Christophers E, Sehröder JMA. Possible mechanism of Th2-dependent eosinophil recruitment in allergic and atopic diseases. J Invest Dermatol 1997; 108: 539 (Abstr.).
14. Vandermeeren M, Janssens S, Boergers M, Geysen J. Dimethylfumarate is an inhibitor of cytokine-induced E-selectin. VCAM-1, and ICAM-1 expression in human endothelial cells. Biochem Biophys Res Commun 1997; 234: 19-23.